Mackenzie Financial Corp Sells 893,578 Shares of Pfizer Inc. (NYSE:PFE)

Mackenzie Financial Corp decreased its holdings in shares of Pfizer Inc. (NYSE:PFE) by 50.1% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 891,118 shares of the biopharmaceutical company’s stock after selling 893,578 shares during the period. Mackenzie Financial Corp’s holdings in Pfizer were worth $24,933,000 as of its most recent SEC filing.

Other institutional investors also recently added to or reduced their stakes in the company. Gilbert & Cook Inc. grew its holdings in shares of Pfizer by 3.8% in the 4th quarter. Gilbert & Cook Inc. now owns 25,651 shares of the biopharmaceutical company’s stock worth $738,000 after purchasing an additional 945 shares during the last quarter. Gryphon Financial Partners LLC increased its holdings in shares of Pfizer by 43.7% during the fourth quarter. Gryphon Financial Partners LLC now owns 26,942 shares of the biopharmaceutical company’s stock worth $861,000 after buying an additional 8,194 shares in the last quarter. Evoke Wealth LLC raised its stake in shares of Pfizer by 14.4% in the fourth quarter. Evoke Wealth LLC now owns 44,427 shares of the biopharmaceutical company’s stock valued at $1,279,000 after acquiring an additional 5,597 shares during the last quarter. Tradition Wealth Management LLC boosted its holdings in shares of Pfizer by 18.2% in the 4th quarter. Tradition Wealth Management LLC now owns 16,791 shares of the biopharmaceutical company’s stock worth $483,000 after acquiring an additional 2,583 shares in the last quarter. Finally, Alberta Investment Management Corp grew its position in Pfizer by 20.9% during the 4th quarter. Alberta Investment Management Corp now owns 186,375 shares of the biopharmaceutical company’s stock worth $5,366,000 after acquiring an additional 32,175 shares during the last quarter. 68.36% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities analysts have issued reports on the company. Cantor Fitzgerald reiterated an “overweight” rating and issued a $45.00 price objective on shares of Pfizer in a research report on Monday, September 16th. Daiwa Capital Markets raised Pfizer from a “neutral” rating to an “outperform” rating and lifted their price target for the company from $28.00 to $34.00 in a report on Wednesday, August 7th. UBS Group increased their price objective on shares of Pfizer from $30.00 to $31.00 and gave the stock a “neutral” rating in a report on Wednesday, July 31st. Wells Fargo & Company boosted their target price on shares of Pfizer from $28.00 to $30.00 and gave the stock an “equal weight” rating in a research note on Wednesday, July 31st. Finally, StockNews.com raised shares of Pfizer from a “hold” rating to a “buy” rating in a research note on Thursday, August 1st. Eight research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $34.54.

Pfizer Price Performance

Shares of PFE stock opened at $29.09 on Friday. The firm’s 50 day moving average price is $29.31 and its two-hundred day moving average price is $28.29. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.60 and a current ratio of 0.86. Pfizer Inc. has a 52-week low of $25.20 and a 52-week high of $34.11. The stock has a market cap of $164.84 billion, a PE ratio of -484.75, a PEG ratio of 1.27 and a beta of 0.68.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, July 30th. The biopharmaceutical company reported $0.60 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.46 by $0.14. Pfizer had a positive return on equity of 8.42% and a negative net margin of 4.66%. The business had revenue of $13.28 billion for the quarter, compared to analyst estimates of $12.96 billion. During the same period last year, the company earned $0.67 EPS. The firm’s revenue was up 2.1% on a year-over-year basis. As a group, analysts forecast that Pfizer Inc. will post 2.66 EPS for the current year.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.